Adavosertib plus gemcitabine for platinum-resistant or platinum-refractory recurrent ovarian cancer: a double-blind, randomised, placebo-controlled, phase 2 trial
Stephanie Lheureux, Mihaela C. Cristea, Jeffrey P. Bruce, Swati Garg, Michael Cabanero, Gina Mantia-Smaldone, Alexander B. Olawaiye, Susan L. Ellard, Johanne I. Weberpals, Andrea E. Wahner Hendrickson, Gini F. Fleming, Stephen Welch, Neesha C. Dhani, Tracy Stockley, Prisni Rath, Katherine Karakasis, Gemma N. Jones, Suzanne Jenkins, Jaime Rodriguez-Canales, Michael TracyQian Tan, Valerie Bowering, Smitha Udagani, Lisa Wang, Charles A. Kunos, Eric Chen, Trevor J. Pugh, Amit M. Oza
Dive into the research topics of 'Adavosertib plus gemcitabine for platinum-resistant or platinum-refractory recurrent ovarian cancer: a double-blind, randomised, placebo-controlled, phase 2 trial'. Together they form a unique fingerprint.